EUVIMEDEUVIMED entdecken
Open Access

Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker

Simeon I Taylor iD, Hua-Ren Cherng, Zhinous Shahidzadeh Yazdi, May E Montasser, Hilary B Whitlatch, Braxton D Mitchell, Alan R Shuldiner, Elizabeth A Streeten, Amber L Beitelshees

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Simeon I Taylor und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glycosuria, Symporters. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To validate pharmacodynamic responses to sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and test for association with genetic variants in SLC5A4 , SLC5A9 , and SLC2A9 .

Methods

Canagliflozin (300 mg), a SGLT2 inhibitor, was administered to 30 healthy volunteers. Several endpoints were measured to assess clinically relevant responses, including drug‐induced increases in urinary excretion of glucose, sodium and uric acid.

Results

This pilot study confirmed that canagliflozin (300 mg) triggered acute changes in mean levels of several biomarkers: fasting plasma glucose (−4.1 mg/dL; P = 6 × 10 −5 ), serum creatinine (+0.05 mg/dL; P = 8 × 10 −4 ) and serum uric acid (−0.90 mg/dL; P = 5 × 10 −10 ). The effects of sex on glucosuria depended upon how data were normalized. Whereas males' responses were ~60% greater when data were normalized to body surface area, males and females exhibited similar responses when glucosuria was expressed as grams of urinary glucose per gram‐creatinine. The magnitude of glucosuria was not significantly correlated with fasting plasma glucose, estimated glomerular filtration rate or age in those healthy individuals without diabetes with an estimated glomerular filtration rate of more than 60 mL/min/1.73m 2 .

Conclusions

Normalizing data relative to creatinine excretion will facilitate including data from males and females in a single analysis. Furthermore, because our ongoing pharmacogenomic study (NCT02891954) is conducted in healthy individuals, this will facilitate detection of genetic associations with limited confounding by other factors such as HbA1c and renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2GlycosuriaSymportersMaleFemaleHumansCanagliflozinUric AcidHypoglycemic AgentsBlood GlucoseCreatininePharmacogeneticsPilot ProjectsGlucosidesGlucoseBiomarkersGlomerular Filtration RateGlucose Transport Proteins, Facilitative

Stichwörter der Autor:innen

canagliflozindiabeteskidneypharmacogenomicsprecision medicinesex as a biological variablesodium-glucose co-transporter-2type 2 diabetesuric acid

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCanagliflozinUric AcidHypoglycemic AgentsBlood GlucoseCreatinineGlucosidesGlucoseBiomarkersSymporters

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Simeon I Taylor

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Taylor, S. I., Cherng, H. R., Shahidzadeh Yazdi, Z., Montasser, M. E., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Streeten, E. A., & Beitelshees, A. L. (2023). Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15246

Vancouver

Taylor SI, Cherng HR, Shahidzadeh Yazdi Z, Montasser ME, Whitlatch HB, Mitchell BD, et al. Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15246

BibTeX
@article{Taylor2023,
  author = {Taylor, Simeon I and Cherng, Hua-Ren and Shahidzadeh Yazdi, Zhinous and Montasser, May E and Whitlatch, Hilary B and Mitchell, Braxton D and Shuldiner, Alan R and Streeten, Elizabeth A and Beitelshees, Amber L},
  title = {Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15246}
}
Kostenlos starten →